Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

BACKGROUND: MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials. Immunogenicity of MYL-1501D and reference insulin glargine was examined in both studies. METHODS: INSTRIDE 1...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:BMC Endocr Disord
Hoofdauteurs: Sun, Bin, Sengupta, Nilanjan, Rao, Anita, Donnelly, Charles, Waichale, Vinit, Roy, Arnab Sinha, Ramaswamy, Shilpa, Pathak, Divya, Bowsher, Ronald R., Raiter, Yaron, Aubonnet, Patrick, Barve, Abhijit
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2021
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8235862/
https://ncbi.nlm.nih.gov/pubmed/34174848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-021-00797-4
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items